

FOI 2986

2<sup>nd</sup> April 2025

## FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

**Q1a – How many patients were treated with the following drugs for the following diseases from the start of Oct 2024 to the end of Dec 2024?**

**Please use the latest available 3 months if Oct to Dec is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.**

**Response:**

CURRENT PATIENTS 13/03/2025

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab	259	131	63	218	203	172
Apremilast	0			0		
Bimekizumab	15			1	1	
Brodalumab	6					
Certolizumab Pegol	6			28	23	18
Deucravacitinib	0					
Etanercept	2			69	39	112
Guselkumab	63			16		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	3	47	59	11	8	8
Ixekizumab	112			41	16	
Risankizumab	88	0	0	4		
Secukinumab	30			93	59	
Tildrakizumab	5					
Ustekinumab	24	69	32	1		
Upadacitinib		11	10	6	6	19
Vedolizumab		53	54			
Filgotinib			0			0
Golimumab			1	25	33	16
Mirikizumab			0			
Ozanimod			0			
Etrasimod			0			

Tofacitinib			4	3	0	4
Baricitinib						42
Rituximab						96
Sarilumab						21
Tocilizumab						32

**Q1b – How many patients were treated with Ustekinumab and its biosimilars from the start of Oct 2024 to the end of Dec 2024?**

**Please use the latest available 3 months if Oct to Dec is not available and specify which 3 months has been used.**

**Response:**

CURRENT PATIENTS 13/03/25

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis
Ustekinumab (Stelara)	3	7	6	0
Ustekinumab (Pyzchiva)	0	0	0	0
Ustekinumab (Uzpruvo)	0	0	0	0
Ustekinumab (Wezenla)	21	62	26	1

**Q1c – How many patients were treated with Stelara and its biosimilars (for any disease) in the months Oct 2024, Nov 2024, and Dec 2024?**

**Please use the latest available 3 months if Oct to Dec is not available and specify which 3 months has been used.**

**Response:**

Drug Name	Oct 24	Nov 24	Dec 24
Ustekinumab (Stelara)	133	130	39
Ustekinumab (Biosimilars)	0	0	89

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)